WONDER-02:塑料支架对比腔壁贴合金属支架用于超声内镜引导下胰腺假性囊肿引流——多中心随机非劣效性试验研究方案
WONDER-02试验为多中心、开放标签、非劣效性随机对照试验,计划在日本26个中心纳入80例需超声内镜引导下治疗的胰腺假性囊肿患者,按1:1随机接受塑料支架或腔壁贴合金属支架(LAMS)治疗。主要终点为临床成功,即假性囊肿缩小至≤2 cm且炎症指标改善。该试验旨在评估塑料支架相比LAMS的非劣效性。
要点
- 拟纳入80例胰腺假性囊肿患者,按1:1随机分为塑料支架组和LAMS组各40例。
- 塑料支架组使用两枚7-Fr双猪尾支架进行超声内镜引导下引流。
- 主要终点为临床成功:假性囊肿缩小至≤2 cm且炎症指标改善。
核心结论
- WONDER-02试验将探讨塑料支架对比LAMS在超声内镜引导下治疗症状性胰腺假性囊肿中的疗效与安全性,尤其关注塑料支架的非劣效疗效。
- 研究结果将有助于为该人群建立新的治疗流程。
研究设计与样本
- WONDER-02为多中心、开放标签、非劣效性随机对照试验,计划在日本26个中心纳入80例需超声内镜引导下治疗的胰腺假性囊肿患者。
- 患者按1:1随机分配至塑料支架组或LAMS组,每组40例。
- 塑料支架组使用两枚7-Fr双猪尾支架进行超声内镜引导下引流;LAMS组除使用LAMS外操作方式相同。
- 升级治疗由试验研究者酌情通过内镜和/或经皮操作实施。
主要发现
- 主要终点为临床成功,定义为假性囊肿大小缩小至≤2 cm且炎症指标(即体温、白细胞计数和血清C反应蛋白)改善。
- 次要终点包括技术成功、包括死亡在内的不良事件、假性囊肿复发和医疗费用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoscopic ultrasound (EUS)-guided transluminal drainage has become a first-line treatment modality for symptomatic pancreatic pseudocysts. Despite the increasing popularity of lumen-apposing metal stents (LAMSs), plastic stents may resolve non-necrotic fluid collections effectively with lower costs and no LAMS-specific adverse events. To date, there has been a paucity of data on the appropriate stent type in this setting. This trial aims to assess the non-inferiority of plastic stents to a LAMS for the initial EUS-guided drainage of pseudocysts. METHODS: The WONDER-02 trial is a multicentre, open-label, non-inferiority, randomised controlled trial, which will enrol pancreatic pseudocyst patients requiring EUS-guided treatment in 26 centres in Japan. This trial plans to enrol 80 patients who will be randomised at a 1:1 ratio to receive either plastic stents or a LAMS (40 patients per arm). In the plastic stent group, EUS-guided drainage will be performed using two 7-Fr double pigtail stents. In the LAMS group, the treatment will be performed in the same way except for LAMS use. The step-up treatment will be performed via endoscopic and/or percutaneous procedures at the trial investigator's discretion. The primary endpoint is clinical success, which is defined as a decrease in a pseudocyst size to ≤ 2 cm and an improvement in inflammatory indicators (i.e. body temperature, white blood cell count, and serum C-reactive protein). Secondary endpoints include technical success, adverse events including mortality, pseudocyst recurrence, and medical costs. DISCUSSION: The WONDER-02 trial will investigate the efficacy and safety of plastic stents compared to a LAMS in EUS-guided treatment of symptomatic pancreatic pseudocysts with a particular focus on the non-inferior efficacy of plastic stents. The findings will help establish a new treatment algorithm for this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT06133023 registered on 9 November 2023. UMIN000052647 registered on 30 October 2023. jRCT1032230444 registered on 7 November 2023.
引用
- Saito T, Takenaka M, Kuwatani M, et al. WONDER-02: plastic stent vs. lumen-apposing metal stent for endoscopic ultrasound-guided drainage of pancreatic pseudocysts-study protocol for a multicentre randomised non-inferiority trial. Trials. 2024. PMID: 39182137. doi:10.1186/s13063-024-08373-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。